Abstract
Serummarkers for prostate carcinoma are widely applied for the purpose of early detection of cancer and the differentiation between benign and malignant disease, for the pre-treatment staging of detected prostatic cancers, and for the monitoring of prostate cancer after curative or palliative therapies. This review illustrates the limitations of current markers for prostatic disease in blood en serum. It gives an overview of what is known about PSA and its isoforms, hK2, PSMA, and PSCA, and discusses, based on this information, in what direction current research is developing in order to improve these markers. (C) 2000 Wiley-Liss, Inc.
Author supplied keywords
Cite
CITATION STYLE
Bangma, C. H., & Verhagen, P. C. M. S. (2000). Blood and serum substances for markers of prostate cancer. Microscopy Research and Technique, 51(5), 430–435. https://doi.org/10.1002/1097-0029(20001201)51:5<430::AID-JEMT5>3.0.CO;2-1
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
